How Epstein–Barr virus differently affects lymphoma B cells
Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas
['FUNDING_U01'] · DUKE UNIVERSITY · NIH-11164825
This project will map how Epstein–Barr virus changes individual B cells in adults with EBV-linked non-Hodgkin lymphoma to help guide future treatments.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11164825 on ClinicalTrials.gov |
What this research studies
The research team will use single-cell gene profiling to look at individual EBV-infected B cells from tumors and lab models to see how cell types and states differ. They will combine data from human tumor samples and mouse models to trace how rare cell populations may drive lymphoma growth. By defining which infected cells have dangerous behaviors or resist immune control, the team hopes to point to new targets for therapies or diagnostics. The work focuses on EBV-positive B-cell lymphomas commonly seen in adults, including forms related to immune suppression and endemic Burkitt lymphoma.
Who could benefit from this research
Good fit: Adults with EBV-positive B-cell non-Hodgkin lymphoma who can provide tumor samples or participate in biospecimen-based research would be the most relevant candidates.
Not a fit: People without EBV-positive B-cell lymphoma or those seeking an immediate change in their medical treatment are unlikely to receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this work could reveal specific EBV-infected cell types that cause lymphoma and suggest new targeted treatments or better diagnostic markers.
How similar studies have performed: Single-cell approaches have uncovered important tumor cell diversity in other cancers, but applying this to EBV-infected lymphomas and turning findings into treatments remains a relatively new effort.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LUFTIG, MICAH ALAN — DUKE UNIVERSITY
- Study coordinator: LUFTIG, MICAH ALAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.